HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Post-Pandemic Stocks

883.668

+5.1800.59%

Number of Gainers:8

Number of Losers:7

Number of Flat:2

PE:- -

High:884.571

Open:878.433

Low:868.104

Close:878.487

Volume:59.53M

Turnover:481.66M

Market Cap:597.36B

Float Cap:494.51B

Loading ...

TYK Medicines-B Chairman, President and CEO Wu Yusheng Plans Share Purchase

Harvest Machinery Accelerates Autumn Grain Collection in Garzê, Sichuan

Genfleet-B Completes Share Buyback Worth HK$1.54 Million

ALEBUND-B Wins US FDA Nod to Start Trial of Novel IgA Nephropathy Drug AP308

CSPC Pharmaceutical Gets China Approval for Eye Drug Clinical Trials

MT Newswires Live

ASC36 Obesity Therapy Enters Phase I Trials in the US by Ascletis

Ascletis Pharma - Initiates U.S. Phase I Study for Asc36 Oral Tablets for Obesity

THOMSON REUTERS

SBP Group Unveils Preclinical Findings for Oral STAT6 Degrader TQH5528 at ERS 2026

Sino Biopharm Presents ERS 2026 Preclinical Data for Oral STAT6 Degrader Tqh5528

CSPC Wins China Clinical Trial Approval for Syh2083 Dry Eye Drops

CSPC Pharmaceutical - Syh2083 Eye Drops Obtain Clinical Trial Approval in China

THOMSON REUTERS

Shanghai Fosun Pharma - Receives Nmpa Approval for Phase Ii/Iii Clinical Trial of Fxs5626

THOMSON REUTERS

Fosun Pharma's Subsidiary Obtains Regulatory Nod for FXS5626 Tablet Trial in Vitiligo Indication

UOB Kay Hian Downgrades Ping An Healthcare and Technology to Hold from Buy; Price Target is HK$6.70

MT Newswires Live

Consolidation at the Base Meets Trend Rebound: When Will Kintor Pharma-B Hit the Key Turning Point for a Valuation Recovery?

CSPC Pharmaceutical Group Stock Falls 2.7% in Hong Kong, Underperforms Competitors

BYD Electronic (International) Stock Slips 5.1% in Hong Kong

Sino Biopharm CEO Tse Says AI, Internationalization Anchor Counter-Cyclical Growth Strategy

Hong Kong Stock Market Update | SBP GROUP (01177) Climbs Nearly 3% After TQC3721 Inhalation Powder Data Presented at ERS 2026

Hong Kong Stock Market Alert | ALEBUND-B (09637) Surges Over 6% on Stock Connect Inclusion and Index Membership, Mircera Sales Jump Approximately 105% Boosting Commercial Momentum

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/BK1515/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"Post-Pandemic Stocks","latestPrice":883.6675,"timestamp":1789612183746,"preClose":878.48724,"halted":0,"volume":59529972,"delay":0,"changeRate":0.005897,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":5.180237,"latestTime":"09-17 10:29:43","open":878.4325,"high":884.57117,"low":868.10425,"amount":481660027,"amplitude":0.018745,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1789617600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789608600000,1789617600000],[1789621200000,1789632000000]],"pbRate":1.317311,"peRate":17.071131,"turnoverRate":0.000815,"increases":8,"decrements":7,"flats":2,"marketCap":597360275584,"floatMarketCap":494514771200},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":884.57117,"amplitude":0.018745,"preClose":878.48724,"low":868.10425,"pbRate":"1.317311","latestPrice":883.6675,"volume":59529972,"delay":0,"open":878.4325,"prevYearClose":1190.107,"prevWeekClose":878.789,"prevMonthClose":925.265,"prevQuarterClose":802.777,"fiveDayClose":890.408,"twentyDayClose":941.274,"sixtyDayClose":813.549,"secType":"PLATE","market":"HK","turnoverRate":0.000815,"peRate":17.071131,"marketCap":597360275584,"floatMarketCap":494514771200,"timestamp":1789612183746,"nameCN":"Post-Pandemic Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":8,"down":7,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1136667600","title":"TYK Medicines-B Chairman, President and CEO Wu Yusheng Plans Share Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=1136667600","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136667600?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:26","pubTimestamp":1788873985,"startTime":"0","endTime":"0","summary":"TYK Medicines-B (02410) has announced that its Chairman, Executive Director and President, Dr. Wu Yusheng, has informed the company of his recent share purchases in the open market. Dr. Wu may...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","09939","BK1574","BK1515","159938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176903440","title":"Harvest Machinery Accelerates Autumn Grain Collection in Garzê, Sichuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1176903440","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176903440?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:10","pubTimestamp":1788873056,"startTime":"0","endTime":"0","summary":"On September 8, combine harvesters were deployed to assist in gathering highland barley in Gexia Village, Xise Township, Garzê County.September marks the peak autumn harvest season across the Garzê...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1501","BK1247","BK1515","00241","BK1571","BK1589","BK1142","BK1584","BK1615","BK1502","BK1617","BK1189","HK0000165453.HKD","BK1591","BK1610"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126663144","title":"Genfleet-B Completes Share Buyback Worth HK$1.54 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1126663144","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126663144?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:11","pubTimestamp":1788869514,"startTime":"0","endTime":"0","summary":"On September 8, 2026, GENFLEET-B (02595) announced that it had repurchased a total of 57,000 shares at a cost of HK$1.5418 million.The buyback was executed in accordance with the company's existing...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","159938","02595","09939","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141807270","title":"ALEBUND-B Wins US FDA Nod to Start Trial of Novel IgA Nephropathy Drug AP308","url":"https://stock-news.laohu8.com/highlight/detail?id=1141807270","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141807270?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:06","pubTimestamp":1788869176,"startTime":"0","endTime":"0","summary":"ALEBUND-B (09637) has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AP308, a first-in-class engineered recombinant IgA...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","09637","BK1515","IBBQ","159151","BK1574","MDTX","09939","PSYK","159938","IBBJ","BK1191","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665214203","title":"CSPC Pharmaceutical Gets China Approval for Eye Drug Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2665214203","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665214203?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:13","pubTimestamp":1788862439,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group's (HKG:1093) SYH2083 eye drops received approval from the National Medical Products Administration to begin clinical trials in China.The class 1 innovative drug is being developed for dry eye disease, according to a Tuesday Hong Kong bourse filing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KURE","LU0067412154.USD","SG9999004220.SGD","LU1993786604.SGD","IE0008368742.USD","IE00BZ08YT58.USD","LU1807302812.USD","LU0880133367.SGD","LU1226287792.SGD","IE0008369823.USD","HK0000165453.HKD","LU1813983027.USD","BK1515","IE00B543WZ88.USD","LU0140636845.USD","LU1951186391.HKD","LU0501845795.SGD","LU1226287875.USD","LU0072913022.USD","IE00B031HY20.USD","IE00BZ08YR35.GBP","LU1226288253.USD","LU2039709279.SGD","LU1960683339.HKD","LU1226287529.USD","LU0314109678.HKD","01093","BK1521","LU1328277881.USD","IE00BZ08YS42.EUR","LU1008478684.HKD","LU1226288170.HKD","BK1191","IE00B5MMRT66.SGD","LU0315179316.USD","LU1152091754.HKD","LU1152091168.USD","LU0326950275.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164928784","title":"ASC36 Obesity Therapy Enters Phase I Trials in the US by Ascletis","url":"https://stock-news.laohu8.com/highlight/detail?id=1164928784","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164928784?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:06","pubTimestamp":1788861983,"startTime":"0","endTime":"0","summary":"Ascletis Pharma-B (01672) has announced the initiation of its Phase I clinical study in the United States for ASC36, an oral amylin receptor agonist peptide designed to treat obesity, following...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1574","01672","BK1161","BK1515","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665932180","title":"Ascletis Pharma - Initiates U.S. Phase I Study for Asc36 Oral Tablets for Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2665932180","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665932180?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:01","pubTimestamp":1788861676,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nFWN44Z0L3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","01672","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127409678","title":"SBP Group Unveils Preclinical Findings for Oral STAT6 Degrader TQH5528 at ERS 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1127409678","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127409678?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:54","pubTimestamp":1788861263,"startTime":"0","endTime":"0","summary":"SBP GROUP has announced that its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., presented preclinical study data for TQH5528, an oral STAT6 degrader, at the European Respiratory...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YS42.EUR","BK1515","IE00BZ08YR35.GBP","HK0000165453.HKD","BK1589","IE00BZ08YT58.USD","01177","BK1191","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665291593","title":"Sino Biopharm Presents ERS 2026 Preclinical Data for Oral STAT6 Degrader Tqh5528","url":"https://stock-news.laohu8.com/highlight/detail?id=2665291593","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665291593?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:51","pubTimestamp":1788861070,"startTime":"0","endTime":"0","summary":"Sino Biopharm presents ERS 2026 preclinical data for oral STAT6 degrader TQH5528Sino Biopharmaceutical disclosed preclinical data for TQH5528, an oral STAT6 degrader, already presented at ERS 2026.Stu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDLb1BcpX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","BK1191","BK1515","01177","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","BK1589","HK0000165453.HKD","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329613","title":"CSPC Wins China Clinical Trial Approval for Syh2083 Dry Eye Drops","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329613","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665329613?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:47","pubTimestamp":1788860844,"startTime":"0","endTime":"0","summary":"CSPC wins China clinical trial approval for SYH2083 dry eye dropsCSPC received China NMPA clearance to start clinical trials of SYH2083 eye drops, a small-molecule novel drug.Initial indication target","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL4D1fT5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","LU1008478684.HKD","LU1993786604.SGD","LU0067412154.USD","KURE","LU1226287875.USD","LU2039709279.SGD","IE00B543WZ88.USD","SG9999004220.SGD","BK1191","01093","IE00BZ08YT58.USD","LU1226288253.USD","IE00BZ08YS42.EUR","LU1226287792.SGD","LU1152091168.USD","LU0315179316.USD","LU0326950275.SGD","LU1813983027.USD","LU0140636845.USD","LU1226288170.HKD","IE0008369823.USD","BK1521","IE0008368742.USD","BK1515","LU1951186391.HKD","LU0501845795.SGD","LU1226287529.USD","LU1152091754.HKD","LU0314109678.HKD","LU1960683339.HKD","IE00B031HY20.USD","LU0072913022.USD","LU1807302812.USD","LU1328277881.USD","LU0880133367.SGD","HK0000165453.HKD","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329660","title":"CSPC Pharmaceutical - Syh2083 Eye Drops Obtain Clinical Trial Approval in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329660","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665329660?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:47","pubTimestamp":1788860822,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nFWN44Z0GM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1226288253.USD","LU1226287792.SGD","IE00B543WZ88.USD","LU0315179316.USD","LU1152091168.USD","LU0067412154.USD","LU0072913022.USD","LU1993786604.SGD","IE00B5MMRT66.SGD","LU1807302812.USD","IE00BZ08YR35.GBP","LU1226287529.USD","IE0008368742.USD","IE0008369823.USD","LU1960683339.HKD","LU1226287875.USD","LU1951186391.HKD","LU0314109678.HKD","LU0326950275.SGD","LU1008478684.HKD","BK1521","LU0880133367.SGD","LU1152091754.HKD","BK1515","IE00BZ08YS42.EUR","LU0140636845.USD","LU1226288170.HKD","IE00BZ08YT58.USD","LU1813983027.USD","LU1328277881.USD","01093","KURE","BK1191","SG9999004220.SGD","IE00B031HY20.USD","HK0000165453.HKD","LU2039709279.SGD","LU0501845795.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665932955","title":"Shanghai Fosun Pharma - Receives Nmpa Approval for Phase Ii/Iii Clinical Trial of Fxs5626","url":"https://stock-news.laohu8.com/highlight/detail?id=2665932955","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665932955?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:44","pubTimestamp":1788860689,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nFWN44Z0IU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0012","BK1593","BK0239","BK0028","BK0175","02196","BK0183","BK1515","BK0196","BK0096","BK1191","BK0060","600196","BK0187","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132147233","title":"Fosun Pharma's Subsidiary Obtains Regulatory Nod for FXS5626 Tablet Trial in Vitiligo Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=1132147233","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132147233?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:20","pubTimestamp":1788859248,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SH: 600196) has announced that its controlling subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., recently received approval...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","MDTX","BK0183","BK1515","BK1593","IBBQ","BMED","600196","PSYK","BK0060","02196","BK0175","BK0188","BK0028","BK0096","BK0239","BK0196","IBBJ","BK0012","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665332699","title":"UOB Kay Hian Downgrades Ping An Healthcare and Technology to Hold from Buy; Price Target is HK$6.70","url":"https://stock-news.laohu8.com/highlight/detail?id=2665332699","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665332699?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:16","pubTimestamp":1788858965,"startTime":"0","endTime":"0","summary":"Ping An Healthcare and Technology (HKG:1833) has an average rating of overweight and mean price target of HK$9.41, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and ec","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1247","BK1617","BK1219","BK1515","01833","BK1571","BK1142","BK1615"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150107003","title":"Consolidation at the Base Meets Trend Rebound: When Will Kintor Pharma-B Hit the Key Turning Point for a Valuation Recovery?","url":"https://stock-news.laohu8.com/highlight/detail?id=1150107003","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150107003?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:48","pubTimestamp":1788857312,"startTime":"0","endTime":"0","summary":"On the morning of September 7, KINTOR PHARMA-B (09939) announced that its human long-term safety trial for KT-939, a novel and highly effective tyrosinase inhibitor developed in-house to suppress...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1574","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665325339","title":"CSPC Pharmaceutical Group Stock Falls 2.7% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2665325339","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665325339?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:32","pubTimestamp":1788856320,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of CSPC Pharmaceutical Group Ltd. slid 2.7% to 9.42 Hong Kong dollars on what proved to be an all-around rough trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.4% to 25317.18.This was the stock's second consecutive day of losses.CSPC Pharmaceutical Group Ltd. closed 19% short of its 52-week high of HK$11.63, which the company reached Sept. 9.The stock underperformed when compared to some of its competitors, as Sino Biopharmaceutical Ltd. rose 6.9%, SSY Group Ltd. fell 0.9%, and United Laboratories International Holdings Ltd. rose 0.5%.Trading volume totaled 71.8 million shares, compared to the 50-day average of 105.6 million shares.Data source: Dow Jones Market Data, FactSet","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0008368742.USD","IE00BZ08YR35.GBP","IE00B031HY20.USD","LU0072913022.USD","LU1951186391.HKD","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","LU0315179316.USD","LU0314109678.HKD","SG9999004220.SGD","LU0067412154.USD","LU1226288253.USD","LU1226287529.USD","LU1152091754.HKD","LU1226287792.SGD","LU1152091168.USD","LU0501845795.SGD","BK1191","BK1521","IE0008369823.USD","LU1328277881.USD","LU0326950275.SGD","LU1960683339.HKD","LU1807302812.USD","LU0140636845.USD","LU2039709279.SGD","01093","LU1008478684.HKD","LU1226287875.USD","KURE","LU1813983027.USD","IE00B5MMRT66.SGD","LU1226288170.HKD","LU1993786604.SGD","LU0880133367.SGD","HK0000165453.HKD","IE00B543WZ88.USD","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665325355","title":"BYD Electronic (International) Stock Slips 5.1% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2665325355","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665325355?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:31","pubTimestamp":1788856260,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of BYD Electronic  Co. Ltd. shed 5.1% to 25.52 Hong Kong dollars on what proved to be an all-around grim trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.4% to 25317.18.The stock's fall snapped a two-day winning streak.BYD Electronic  Co. Ltd. closed 43% below its 52-week high of HK$44.60, which the company achieved Oct. 2.The stock underperformed when compared to some of its competitors, as Times Universal Group Holdings Ltd. remained unchanged.Trading volume totaled 12.3 million shares, compared to the 50-day average of 12.6 million shares.Data source: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1582","BK1607","BK1149","BK1540","LU0274383008.USD","BK1515","LU0348767384.USD","BK1167","BK1589","BK1580","BK1504","00285","LU0348766576.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665341408","title":"Sino Biopharm CEO Tse Says AI, Internationalization Anchor Counter-Cyclical Growth Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2665341408","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665341408?lang=en_us&edition=fundamental","pubTime":"2026-09-08 11:51","pubTimestamp":1788839513,"startTime":"0","endTime":"0","summary":"Sino Biopharm CEO Tse says AI, internationalization anchor counter-cyclical growth strategySino Biopharmaceutical CEO Eric Tse told the Yabuli Forum on Sept. 5 it is pursuing counter-cyclical growth t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL2RNzg9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2293690082.USD","LU0640478417.SGD","LU0963555726.SGD","LU1153585028.USD","LU0949170426.SGD","LU0969580561.USD","LU0738911758.USD","LU1019632923.USD","LU0211326755.USD","LU1863844749.USD","IE00BFTCPJ56.SGD","LU1267930813.SGD","LU2091194634.USD","LU0011850046.USD","BK1515","LU0784385840.USD","LU2433249047.HKD","LU1863844665.USD","LU0882574055.USD","LU0077335932.USD","LU0158827948.USD","LU0029864427.USD","BK5011","LU1051770623.HKD","LU0827474353.SGD","LU0960981461.USD","AZN.UK","01177","LU0128525689.USD","LU0972486137.USD","LU2237443978.SGD","LU2279689827.SGD","LU0345777659.USD","LU2125909247.SGD","LU1323610961.USD","LU0211328371.USD","LU0859254822.USD","LU0889566641.SGD","LU1355424745.HKD","IE00BZ08YS42.EUR","LU0887340254.USD","LU0052756011.USD","03165","LU0047473722.SGD","LU1119994496.HKD","LU2133065610.SGD","HK0000165453.HKD","LU0211327993.USD","LU1196032939.SGD","LU0128525929.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184154136","title":"Hong Kong Stock Market Update | SBP GROUP (01177) Climbs Nearly 3% After TQC3721 Inhalation Powder Data Presented at ERS 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1184154136","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184154136?lang=en_us&edition=fundamental","pubTime":"2026-09-08 10:50","pubTimestamp":1788835817,"startTime":"0","endTime":"0","summary":"Shares of SBP GROUP (01177) advanced nearly 3% in Hong Kong trading, last up 2.74% at HK$5.62 with turnover reaching HK$111 million.On September 7, the company announced that its subsidiary, Chia Tai...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YT58.USD","BK4588","HK0000165453.HKD","BK1521","KCAI","BK1589","VXUS","IE00BZ08YS42.EUR","BK4585","01177","BK1191","IE00BZ08YR35.GBP","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183000307","title":"Hong Kong Stock Market Alert | ALEBUND-B (09637) Surges Over 6% on Stock Connect Inclusion and Index Membership, Mircera Sales Jump Approximately 105% Boosting Commercial Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=1183000307","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183000307?lang=en_us&edition=fundamental","pubTime":"2026-09-08 10:22","pubTimestamp":1788834140,"startTime":"0","endTime":"0","summary":"ALEBUND-B (09637) shares climbed more than 6% in Monday's session, trading up 6.02% at HK$28.52 as of the time of writing. The stock recorded a turnover of HK$6.452 million with a volume ratio of...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","BK1515","FLHK","HSCI","KCAI","BK1191","BK4585","09637","BK1574","09939","VXUS","BK4588","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":6,"totalSize":179,"code":"91000000","status":"200"}]}}